FDA Panel Backs Landmark Cancer Blood Test That Screens for 50 Tumors at Once

The FDA's advisory panel voted 7-2 to endorse Grail's Galleri blood test, a first-of-its-kind screening tool designed to detect signs of up to 50 different cancers from a single blood draw. The molecular and clinical genetics panel concluded the benefits outweigh the risks for adults over 50, marking the first time a multi-cancer early detection (MCED) test has received such backing from federal advisers.

Vital Signs

Key numbers from the hearing:

• 10-0 —...